Extension to in-use stability time FARNBOROUGH, England, [23] March, 2020: Flexipharm Austrading, … Continue reading “Flexipharm Austrading announces product update on Arsenic Trioxide Phebra”
17 March 2020, London, Geneva & Jersey – Medicxi, the leading European … Continue reading “Medicxi Bolsters and Expands Team with Senior Industry Leaders”
NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment … Continue reading “NeoPhore appoints Dr Matthew Baker as Chief Executive Officer”
Supports Vaccinex’s diversification into clinical development of pepinemab for Alzheimer’s disease IXICO … Continue reading “IXICO announces an expanded contract for its imaging services with Vaccinex”
Currently in Phase 2b development for the treatment of life-threatening fungal infections … Continue reading “F2G Receives US FDA Orphan Drug Designation for Olorofim”
Targeting smaller voids in foot and ankle, orthopaedic reconstruction and trauma Keele, … Continue reading “Biocomposites announces U.S. launch of new STIMULAN® Rapid Cure 3cc product”
Amsterdam, The Netherlands, February 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or … Continue reading “Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors”
Geneva, Switzerland, 26 February 2020: iOnctura SA., a clinical stage biopharmaceutical company, developing … Continue reading “iOnctura announces first patient dosed in a phase I clinical study of its novel highly selective PI3Kδ inhibitor, IOA-244 for solid tumours”
Cardiff and London UK, February 25, 2020 – TrakCel, a leading software … Continue reading “TrakCel and Ori Biotech sign a collaboration agreement for supply chain orchestration within cell and gene therapy manufacturing”
Novo Seeds, the early stage investment and company creation team of Novo … Continue reading “Novo Seeds Portfolio Company IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Trial in First Line Non-small Cell Lung Cancer”
We will be presenting a scientific poster on enhancing imaging analysis accuracy … Continue reading “IXICO to present AI segmentation research at Huntington’s Disease Therapeutics Conference”
Amsterdam, Netherlands and Hoboken, New Jersey: February 17, 2020: Castor, a health-tech company … Continue reading “Castor provides free access to data capture platform to support non-profit COVID-19 research projects”
CAMBRIDGE, UK and NEW YORK, USA, 10 February 2020 Artios Pharma Limited … Continue reading “Artios Pharma Strengthens Clinical Development Team with Senior Appointments”
Geneva, Switzerland, 4th February 2020: iOnctura SA, a clinical stage biopharmaceutical company, … Continue reading “iOnctura Expands its Clinical Advisory Board”
vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for … Continue reading “vasopharm completes patient enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)”
LONDON, Jan. 28, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) … Continue reading “Verona Pharma to Present at LSX World Congress 2020”
Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”
Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”
Amsterdam, The Netherlands, January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical … Continue reading “iOnctura raises EUR 15 million in Series A financing to progress its pipeline into clinical development”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com